On August 28, CHINA FEIHE (06186) released its 2025 interim results report. During the reporting period, the company achieved operating revenue of 9.15 billion yuan (RMB, same below), net profit of 1.03 billion yuan, and robust cash flow of 6.48 billion yuan, demonstrating solid operational fundamentals and financial resilience. In the first half of 2025, Feihe's infant formula maintained its leading position in both overall market share and sales volume across all channels.

During the period, Feihe drove development through advanced technology innovation, launching its "Milk Protein Fresh Extraction Technology" and China's first comprehensive HMOs database, continuously strengthening its technological competitive advantages. The accelerated internationalization strategy achieved significant results, with the North American market expanding to over 1,500 supermarket locations and overseas store count growing 270% year-over-year. Southeast Asian expansion progressed simultaneously, with successful market entry into the Philippines.

The company announced plans to invest 1 billion yuan in share buybacks and distribute approximately 1 billion yuan in interim dividends, with expected total dividend payments for 2025 of no less than 2 billion yuan, demonstrating tangible returns to investor confidence. Additionally, Feihe pioneered the launch of a 1.2 billion yuan birth subsidy program, actively responding to national policies and expected to benefit over 800,000 newborn families, fulfilling its corporate social responsibility as an industry leader and anchoring long-term development value.